Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early access, adaptive licensing & ''breakthrough'' designation – UK expert group's wish list

This article was originally published in Scrip

Executive Summary

A group of experts has called on the UK regulator, the MHRA, to sort out funding issues regarding its proposed early access to medicines scheme and to get the project up and running "as soon as possible". It also urges the European Medicines Agency to speed up its delayed adaptive licensing project, and calls for a designation similar to the "breakthrough therapy" status that was recently introduced in the US.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel